Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Autologous Dendritic Cell Vaccine in PD-L1 Negative Advanced Mesothelioma
NCT03546426Phase 1Active, not recruiting
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Dec 2019
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial in malignant mesothelioma (MM), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Adverse Events. Started Dec 2019; status: active, not recruiting.
02
Conditions
malignant mesothelioma (MM)
Beyond the preview
Go deeper on NCT03546426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546426.